Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Doug Drysdale

Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business results ended March 31, 2022.

Benzinga · Jun 22, 2022

10 Psychedelics CEOs To Pay Attention To In 2022

By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.

Benzinga · Jun 22, 2022

Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support

Elon Musk, the Tesla multi-billionaire investor and owner of the largest portion of Twitter (NYSE: TWTR) shares has been discus

Benzinga · Jun 10, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin

Cybin Inc. (NEO:CYBN) (NYSE American: CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study from Entheon Biomedical Corp.

Benzinga · Jun 7, 2022

Pilot Study By Cybin Shows That Ketamine Modifies Connectivity Between Brain Regions

Cybin Inc. (NYSE:CYBN) and Kernel, two companies that undertook a joint feasibility study to evaluate the effects ketamine has on blood flow in the brain in late March,&nbs

Benzinga · May 9, 2022

EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space

Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock. In the psychedelic space, catalysts could be even more important, as the industry as a whole is still in its infancy.

Benzinga · Apr 19, 2022

EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you.

Benzinga · Apr 19, 2022

Read news from The Economist, FT, and more,
with one subscription

Cybin's CYB0004 Shows Positive Preclinical Results Over Traditional Psychedelics

CYB004 is one of Cybin’s (NYSE:CYBN) proprietary second-generation psychedelics, developed to treat depression, anxiety, and substance abuse disorders. According to the company, the substance has recently shown positive preclinical data over DMT, the molecule from which it is derived. Cybin has observed that the preclinical study showed promising results for…

Benzinga · Apr 13, 2022

WIPO Publishes Cybin's Patent Application For Inhaled Psychedelics Therapies

Cybin Inc. (NYSE:CYBN) announced that the World Intellectual Property Organization (WIPO) published an international patent application covering a range of inhalation delivery methods for psychedelic molecules. “Our progress to secure IP for unique psychedelic delivery methods strongly aligns and supports our current CYB004 pipeline program of deuterated DMT via inhalation,…

Benzinga · Apr 8, 2022

A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers

From his beginnings at DuPont Merck to his current position as Cybin’s (NYSE:CYBN) CEO, Doug Drysdale has certainly had an eventful career. “I seem to be drawn to opportunities that are poised for growth, whether that is from being undermanaged, distressed or a startup situation,” he said in an interview, explaining his…

Benzinga · Apr 6, 2022

Cybin Begins Study Using Kernel Flow Headsets To Measure Ketamine's Effects On The Brain

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway, announced Cybin Inc. (NYSE:CYBN), which is sponsoring the research that will make heavy use of Kernel Flow, a quantitative neuroimaging technology. Without the need for a more expensive and oversized piece of equipment, Kernal Flow…

Benzinga · Mar 31, 2022

Cybin Completes In Vivo Preclinical Studies For Major Depressive Disorder

Cybin Inc. (NYSE:CYBN) announced that its in vivo preclinical studies evaluating the proprietary drug CYB003 are completed. The goal is to analyze the potential of the compound in treating major depressive disorder (MDD). The studies were carried out on multiple species and included several doses of the substance, which were reportedly…

Benzinga · Mar 29, 2022

EXCLUSIVE: How This Company Backed By Deepak Chopra & Tony Robbins Is Disrupting Mental Health With Psychedelics

Doug Drysdale, CEO of Cybin Inc. (NYSE: CYBN) recently joined Javier Hasse and Elliot Lane on the Benzinga Cannabis Insider show.

Benzinga · Feb 25, 2022

Coverage From

Benzinga

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University of East Anglia

24 stories

University of Calgary

17 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.